Investors injected $37 million into OvaScience Inc. last week so the fertility company can produce clinical data proving its egg precursor stem cell technology can improve the success rate of in vitro fertilization. The cash should last through 2014, at which point an initial treatment should be ready for market launch.

OvaScience's technology is predicated on the discovery by its scientific founder that a woman's ovary contains egg precursor stem cells